keyword
MENU ▼
Read by QxMD icon Read
search

Vinorelbine

keyword
https://www.readbyqxmd.com/read/29449740/does-v600e-braf-mutation-predict-vinorelbine-efficacy-a-proof-of-concept-from-a-lung-micropapillary-adenocarcinoma-metastatic-to-the-breast
#1
P Carassai, G Jocollé, G Donati, S Spinazzé, C Baiocco, P Baderna, A Martinet, F Lococo, F Migliaccio, G Rossi
BRAF mutations occur in about 3% of all lung adenocarcinomas and V600E missense mutation characterizes about half of BRAF -mutated lung adenocarcinomas and is significantly associated with micropapillary pattern and shorter disease-free and overall survival rates. In this report, we report a challenging case of a patient with a metastatic micropapillary adenocarcinoma of the lung harbouring V600E BRAF mutation who experienced a surprising protracted clinical response to metronomic vinorelbine. The possible association between the V600E BRAF mutation pathway and the effective use of vinca alkaloid is discussed...
December 2017: Pathologica
https://www.readbyqxmd.com/read/29429891/vinorelbine-potently-induces-placental-cell-death-does-not-harm-fertility-and-is-a-potential-treatment-for-ectopic-pregnancy
#2
Roxanne Hastie, Elgene Lim, Pavel Sluka, Lisa Campbell, Andrew Horne, Lenore Ellett, Natalie J Hannan, Fiona Brownfoot, Tu'uhevaha J Kaitu'u-Lino, Stephen Tong
Ectopic pregnancies complicate 1-2 pregnancies and are a leading cause of maternal death. An effective oral drug therapy that replaces surgery might make its treatment safer, cheaper, simpler and therefore more widely accessible. The only current medical treatment offered to women is intramuscular methotrexate, but this only reliably resolves smaller ectopic pregnancies. As such, many ectopic pregnancies require surgical excision. We show that vinorelbine, an orally available chemotherapeutic agent, potently induced placental cell death but did not harm fertility in mice...
February 2, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29427392/determination-of-16-antineoplastic-drugs-by-capillary-electrophoresis-with-uv-detection-applications-in-quality-control
#3
Nicolas Guichard, Marie Ogereau, Ludivine Falaschi, Serge Rudaz, Julie Schappler, Pascal Bonnabry, Sandrine Fleury-Souverain
Two capillary electrophoresis (CE) methods were developed for the analysis of 16 antineoplastic drugs contained in injectable pharmaceutical formulations. A capillary zone electrophoresis (CZE) method coupled to UV was developed with a background electrolyte (BGE) made of a 100 mM phosphate buffer at pH 2.5 containing 50% (v/v) of acetonitrile and dynamic coating of capillaries with Ceofix®. This method allowed the analysis of doxorubicin, epirubicin, idarubicin, daunorubicin, irinotecan, topotecan, vincristine, vindesine, vinblastine, and vinorelbine in less than 8 min...
February 10, 2018: Electrophoresis
https://www.readbyqxmd.com/read/29424562/synthesis-and-antitumor-evaluation-of-hybrids-of-5-8-dioxo-5-8-dihydroisoquinoline-4-carboxylates%C3%A2-and%C3%A2-carbohydrates
#4
Wanderson A da Silva, Luiz Crp da Silva, Vinicius R Campos, Maria Cbv de Souza, Vitor F Ferreira, Ângela Cpb Dos Santos, Plínio C Sathler, Gabriella S de Almeida, Flaviana Rf Dias, Lucio M Cabral, Rodrigo Bv de Azeredo, Anna C Cunha
AIM: Cancer has emerged as a growing public health problem in many parts of the world. METHODOLOGY: We describe the synthesis of a series of carbohydrate-based isoquinoline-5,8-diones through the 1,4-addition reaction between 5,8-dioxo-5,8-dihydroisoquinoline and aminocarbohydrates. Halogenated quinones were also synthesized. Their inhibitory effects on the proliferation of human cancer cell lines were studied. RESULTS & CONCLUSION: The most promising compound, derived from isoquinoline-5,8-dione, containing ribofuranosidyl ring, was selectively active in vitro against H1299 cancer cells, with 1...
February 9, 2018: Future Medicinal Chemistry
https://www.readbyqxmd.com/read/29416938/complete-response-in-advanced-breast-cancer-patient-treated-with-a-combination-of-capecitabine-oral-vinorelbine-and-dasatinib
#5
V Sgroi, M Bassanelli, M Roberto, E Iannicelli, R Porrini, P Pellegrini, A Tafuri, P Marchetti
Background: Currently, there are no data available on the best choice of treatment in heavily pretreated patients with advanced breast cancer. However, the combination of oral vinorelbine and capecitabine has been demonstrated to be effective and safe in patients with advanced breast cancer pretreated with anthracycline. Furthermore, some studies assessed the activity of dasatinib, an oral tyrosine kinase inhibitor that inhibits five oncogenic tyrosine kinase families, alone or in combination with different chemotherapy in patients affected with advanced breast cancer...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29398647/pegylated-filgrastim-versus-filgrastim-for-stem-cell-mobilization-in-multiple-myeloma-after-novel-agent-induction
#6
Muhammad Bilal Abid, Sanjay De Mel, Muhammad Abbas Abid, Eng Soo Yap, Sathish Kumar Gopalakrishnan, Yunxin Chen, Yi Ching Yuen, Hung Chew Wong, Adeline Lin, Li Mei Poon, Liang Piu Koh, Wee Joo Chng, Lip Kun Tan
BACKGROUND: The current standard of care for transplant-eligible myeloma patients is novel agent-based induction, followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSCs) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness...
January 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29381935/salvage-chemoradiotherapy-with-cisplatin-and-vinorelbine-for-postoperative-locoregional-recurrence-of-non-small-cell-lung-cancer
#7
Kakeru Hisakane, Kiyotaka Yoh, Naoki Nakamura, Hibiki Udagawa, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Seiji Niho, Tetsuo Akimoto, Masahiro Tsuboi, Koichi Goto
Although a few investigators have demonstrated the effect of concurrent chemoradiotherapy (CRT) for postoperative recurrent non-small cell lung cancer (NSCLC), the outcome of this treatment remains unclear. The aim of this study was to elucidate the efficacy and tolerability of concurrent CRT with cisplatin (CDDP) and vinorelbine (VNR) in patients with postoperative locoregional recurrent NSCLC. A total of 40 patients who had received concurrent CRT with CDDP and VNR between January 1999 and December 2014 were retrospectively analyzed...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29361614/-systemic-treatment-of-malignant-pleural-mesothelioma
#8
Takashi Nakano
Malignant pleural mesothelioma(MPM)is a highly aggressive tumor with a poor prognosis and an increasing incidence worldwide. The only standard first-line chemotherapy for patients with unresectable MPM is cisplatin(CDDP)plus peme- trexed(PEM)(CDDP/PEM), with a median overall survival of about 12months and a median progression-free survival(PFS) of less than 6 months. There are no treatments with proven benefit on survival for relapsed MPM patients. Therefore, novel therapeutic strategies are urgently required...
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29354957/-effects-of-fire-needle-on-quality-of-life-in-patients-with-chemotherapy-of-non-small-cell-lung-cancer
#9
Wenya Pei, Shiyu Lin, Jingchun Zeng, Guifeng Qian, Lizhu Lin, Guohua Lin
OBJECTIVE: To observe the effect difference between fire needle combined with chemotherapy and fire needle on quality of life in patients with chemotherapy of non-small cell lung cancer (NSCLC). METHODS: With randomized controlled method, a total of 60 patients with chemotherapy of NSCLC were divided into an observation group (fire-needle plus chemotherapy group) and a control group (chemotherapy group), 30 cases in each one. The observation group was treated with fire needle at Sihua points which consisted of Geshu (BL 17) and Danshu (BL 19), combined with chemotherapy selected from TP (paclitaxel+cisplatin)/GP (gemcitabine+cisplatin)/DP (docetaxel+cisplatin)/NP (vinorelbine+cisplatin) by the oncologist according to patients' condition...
November 12, 2017: Zhongguo Zhen Jiu, Chinese Acupuncture & Moxibustion
https://www.readbyqxmd.com/read/29350548/use-of-helical-tomotherapy-in-locally-advanced-and-or-metastatic-breast-cancer-for-locoregional-treatment
#10
Laura Thery, Alexandre Arsene-Henry, Susan Carroll, Dominique Peurien, Louis Bazire, Magalie Robilliard, Alain Fourquet, Youlia M Kirova
PURPOSE: Helical tomotherapy (HT) is a new promising tool whose use remains to be studied. This work assesses its impact for local irradiation in terms of side effects, as well as tumour control in locally advanced (LABC) and metastatic breast cancer (MBC). METHODS: We retrospectively reviewed data of 66 patients with LABC and MBC. Patients received standard fractionated radiotherapy by HT, with or without concurrent systemic treatment. RESULTS: The median age was 60 years (28-77)...
January 19, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29344124/molecular-biological-characterization-and-drug-sensitivity-of-chidamide-resistant-non-small-cell-lung-cancer-cells
#11
Song'e Luo, Kai Ma, Hongxia Zhu, Shuren Wang, Mei Liu, Weina Zhang, Shufang Liang, Ningzhi Xu
Chidamide, a histone deacetylase (HDAC) inhibitor, has been applied in clinical trials for various types of hematological and solid tumors. Although acquired resistance is common in chemotherapy, the mechanism of resistance to chidamide is poorly characterized. The goal of the present study was to explore, in detail, the mechanism for the induced resistance to chidamide, and investigate a potential cross-resistance to other chemotherapeutic drugs. A549 cells were exposed to gradually increasing chidamide concentrations to establish a chidamide-resistant non-small cell lung cancer cell line (A549-CHI-R)...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29337963/phase-i-open-label-study-of-afatinib-plus-vinorelbine-in-patients-with-solid-tumours-overexpressing-egfr-and-or-her2
#12
Rastislav Bahleda, Andrea Varga, Yann Bergé, Jean-Charles Soria, David Schnell, Inga Tschoepe, Martina Uttenreuther-Fischer, Jean-Pierre Delord
BACKGROUND: This phase Ib study evaluated afatinib plus vinorelbine in patients with advanced solid tumours overexpressing epidermal growth factor receptor (EGFR) and/or human EGFR 2 (HER2). METHODS: Maximum tolerated doses (MTDs) were determined for afatinib (20, 40 or 50 mg, once daily) combined with standard intravenous vinorelbine (part A; 25 mg m-2 per week) or oral vinorelbine (part B; 60 mg m-2 per week, increased to 80 mg m-2 per week at week 3)...
January 16, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29337265/99mtc-vinorelbine-tartrate-loaded-spherulites-lung-disposition-study-in-sprague-dawley-rats-by-gamma-scintigraphy
#13
Rahul Dhande, Amit Tyagi, Rakesh Kumar Sharma, Hetal Thakkar
Vinorelbine Tartrate (VLB) is the first line chemotherapeutic agent for treatment of Non-Small Cell Lung Cancer, whose non-specific distribution causes unwanted side effects. The aim of the present investigation was to formulate VLB loaded spherulites intended for targeting the lung. Spherulites were composed of Soyabean Phosphatidylcholine (SPC), Cholesterol (Chol), Potassium oleate and Mannitol. Lipid film prepared using SPC, Chol and Potassium oleate, was dispersed in aqueous phase comprising Mannitol and VLB, followed by controlled shearing and extrusion...
January 11, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29321932/acute-onset-of-ulcerative-colitis-during-chemoradiotherapy-for-anaplastic-lymphoma-kinase-positive-lung-adenocarcinoma
#14
Kohei Fujita, Yoshinori Mizumoto, Koki Moriyoshi, Norio Araki, Tadashi Mio
We report a case of acute onset of ulcerative colitis (UC) during chemoradiotherapy in a patient with anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma. A 46-year-old male patient with an abnormal chest shadow was referred to our hospital. He was diagnosed with lung adenocarcinoma, clinical stage T1aN3M0 and stage IIIB. Concurrent chemoradiotherapy was selected for his initial therapy. After two cycles of cisplatin and vinorelbine administration, he experienced persistent diarrhoea and anorexia...
February 2018: Respirology Case Reports
https://www.readbyqxmd.com/read/29318780/the-synergistic-role-of-atp-dependent-drug-efflux-pump-and-focal-adhesion-signaling-pathways-in-vinorelbine-resistance-in-lung-cancer
#15
Takao Nakanishi, Toshi Menju, Shigeto Nishikawa, Koji Takahashi, Ryo Miyata, Kei Shikuma, Terumasa Sowa, Naoto Imamura, Masatsugu Hamaji, Hideki Motoyama, Kyoko Hijiya, Akihiro Aoyama, Toshihiko Sato, Toyofumi F Chen-Yoshikawa, Makoto Sonobe, Hiroshi Date
The vinorelbine (VRB) plus cisplatin regimen is widely used to treat non-small cell lung cancer (NSCLC), but its cure rate is poor. Drug resistance is the primary driver of chemotherapeutic failure, and the causes of resistance remain unclear. By focusing on the focal adhesion (FA) pathway, we have highlighted a signaling pathway that promotes VRB resistance in lung cancer cells. First, we established VRB-resistant (VR) lung cancer cells (NCI-H1299 and A549) and examined its transcriptional changes, protein expressions, and activations...
January 10, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29315394/a-phase-i-ii-study-of-the-combination-of-lapatinib-and-oral-vinorelbine-in-her2-positive-metastatic-breast-cancer
#16
Tom Wei-Wu Chen, Dah-Cherng Yeh, Tsu-Yi Chao, Ching-Hung Lin, Louis Wing-Cheong Chow, Dwan-Ying Chang, Yao-Yu Hsieh, Shu-Min Huang, Ann-Lii Cheng, Yen-Shen Lu, Taiwan Breast Cancer Consortium
Background: The combination of lapatinib and oral vinorelbine for HER2 positive metastatic breast cancer (MBC) is convenient but with uncertain toxicity profiles. A Phase I/II study was designed to understand the tolerability and efficacy of this combination treatment. Method: Female MBC patients with HER2 positive were eligible. Lapatinib was given once daily and oral vinorelbine was given on Days 1 and 8 of a 21-day cycle. A 3 + 3 standard dose-escalation rule was applied in the Phase I study...
January 5, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29276224/feasibility-trial-of-oral-uft-after-platinum-based-adjuvant-chemotherapy-in-patients-with-resected-non-small-cell-lung-cancer
#17
Shigeki Sawada, Ryujiro Sugimoto, Tsuyoshi Ueno, Motohiro Yamashita
We evaluated the feasibility of maintenance treatment using UFT (a combination of tegafur and uracil) after adjuvant platinum-based chemotherapy in patients with resected lung cancer. A prospective feasibility trial was conducted. Between 2010 and 2014, UFT was administered for 2 years sequentially after platinum-based adjuvant chemotherapy in 24 patients with resected Stage IIA-IIIA non-small cell lung cancer. The safety of UFT and the rate of treatment completion were then evaluated. The prior platinum-based chemotherapy regimens consisted of cisplatin+vinorelbine in 16 patients, carboplatin+paclitaxel in 5 and carboplatin+S-1 in one...
December 2017: Acta Medica Okayama
https://www.readbyqxmd.com/read/29246820/mobilization-of-hematopoietic-progenitor-cells-with-standard-or-reduced-dose-filgrastim-after-vinorelbine-in-multiple-myeloma-patients-a-randomized-prospective-single-center-phase-ii-study
#18
Panagiotis Samaras, Markus F Rütti, Burkhardt Seifert, Helga Bachmann, Urs Schanz, Maya Eisenring, Christoph Renner, Antonia Maria Müller, Adrian Schmidt, Axel Mischo, Ivo Fuchs, Mario Bargetzi, Markus G Manz, Roger Stupp, Ulf Petrausch, Frank Stenner-Liewen
Vinorelbine combined with filgrastim (r-metHuG-CSF) at a dose of 10 µg/kg of body weight (BW) per day is a reliable and well tolerated regimen for mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. This prospective randomized phase 2 study was initiated to assess the feasibility of a reduced filgrastim dosage. Vinorelbine was combined with either standard dosed filgrastim (10 µg/kg body weight (BW) per day) or reduced dosed filgrastim (5 µg/kg BW per day). Leukapheresis sessions were planned to start at day 8 and were continued until the predefined target amount of 4 x 106 HPC/kg BW was collected...
December 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29235457/serum-metabolic-profile-alteration-reveals-response-to-platinum-based-combination-chemotherapy-for-lung-cancer-sensitive-patients-distinguished-from-insensitive-ones
#19
Shan Xu, Yanping Zhou, Hui Geng, Dandan Song, Jing Tang, Xianmin Zhu, Di Yu, Sheng Hu, Yanfang Cui
Most lung cancers are diagnosed at fairly advanced stages due to limited clinical symptoms. Platinum-based chemotherapy, either as single regimen or in combination with radiation, is one of the major recommendations for the patients. Earlier evaluation of the effectiveness of the chemotherapies is critical for developing better treatment plan given the toxicity of the chemotherapeutic reagents. Drug efficacy could be reflected in the systemic metabolism characteristics though knowledge about which remains scarce...
December 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29231164/lapatinib-plus-capecitabine-in-patients-with-her2-positive-metastatic-breast-cancer-a%C3%A2-systematic-review%C3%A2
#20
Rebecca Madden, Sam Kosari, Gregory M Peterson, Nasser Bagheri, Jackson Thomas
OBJECTIVE: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 - 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine...
December 12, 2017: International Journal of Clinical Pharmacology and Therapeutics
keyword
keyword
31933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"